PR
PROF.US Profound Medical Corp
- Market cap
- USD 259M
- P/E
- -
- P/B
- 6.33x
- ROE
- -76.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PROF.US undervalued?
Graham numberThe Graham number of Profound Medical Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Profound Medical Corp fundamental analysis
No fundamental analysis for Profound Medical Corp yet.
Profound Medical Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Profound Medical Corp
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or be…
Full company profileProfound Medical Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Profound Medical Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 4.90M | 1.91M | 4.17M | 7.30M | 6.87M | 6.68M | 7.20M | 10.2M | 16.4M | 23.4M |
| Gross Profit | -188K | 1.87M | 605K | 2.39M | 3.47M | 2.95M | 3.02M | 4.38M | 6.70M | 11.6M | 17.9M |
| Operating Income | -16.2M | -17.2M | -14.8M | -14.9M | -18.9M | -30.3M | -32.1M | -28.6M | -31.5M | -42.0M | -35.7M |
| EBITDA | -15.6M | -16.2M | -19.0M | -12.5M | -19.5M | -28.6M | -26.6M | -27.0M | -25.5M | -41.4M | -33.2M |
| Net Income | -12.1M | -19.1M | -15.2M | -15.2M | -21.6M | -30.7M | -28.7M | -28.6M | -26.5M | -43.3M | -32.3M |
| EPS | -2.93 | -3.11 | -1.52 | -1.37 | -1.25 | -1.50 | -1.38 | -1.35 | -1.07 | -1.43 | -0.88 |
| Balance Sheet | |||||||||||
| Total Assets | 17.6M | 22.2M | 34.2M | 29.9M | 105M | 86.7M | 64.4M | 44.0M | 70.2M | 141M | 58.2M |
| Total Liabilities | 6.59M | 10.9M | 14.6M | 15.6M | 7.25M | 6.15M | 12.4M | 12.7M | 9.81M | 74.4M | 15.6M |
| Shareholders' Equity | 11.0M | 11.2M | 19.5M | 14.3M | 97.4M | 80.5M | 52.0M | 31.2M | 60.4M | 66.4M | 42.5M |
| Cash & Short-term Investments | 15.5M | 8.83M | 22.5M | 14.7M | 83.9M | 67.1M | 46.5M | 26.2M | 54.9M | 59.7M | 33.3M |
| Total Debt | 5.90M | 4.18M | 11.6M | 13.0M | 1.68M | 1.38M | 8.23M | 7.87M | 5.12M | 4.71M | 7.36M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -14.5M | -14.9M | -13.4M | -15.4M | -20.6M | -22.4M | -25.8M | -22.6M | -23.5M | -38.9M | -33.2M |
| Capital Expenditure | 809K | 370K | 32.0K | 2.31 | 350K | 593K | 0.00 | 1.96 | 0.00 | 179K | 1.33 |
| Free Cash Flow | -11.6M | -12.2M | -13.4M | -15.4M | -20.9M | -23.0M | -25.8M | -22.6M | -23.5M | -39.1M | -33.2M |
| Ratios | |||||||||||
| ROE | -110.0% | -169.8% | -78.0% | -106.5% | -22.2% | -38.1% | -55.1% | -91.5% | -43.8% | -65.2% | -76.0% |
| ROA | -68.9% | -86.1% | -44.6% | -50.9% | -20.7% | -35.4% | -44.5% | -65.0% | -37.7% | -30.7% | -55.5% |
| Net Profit Margin | - | -389.4% | -797.9% | -364.7% | -296.0% | -446.7% | -429.1% | -396.8% | -260.4% | -264.4% | -137.8% |
| Debt to Equity | 0.53x | 0.37x | 0.59x | 0.91x | 0.02x | 0.02x | 0.16x | 0.25x | 0.08x | 0.07x | 0.17x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Profound Medical Corp dividends
Profound Medical Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Oct 16, 2019.
Who owns Profound Medical Corp
- Insiders 4.12%
- Institutions 45.06%
- Public & others 50.82%
- Shares outstanding 36.6M
- Free float 35.6M
Top funds holding PROF.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity True North Cl F | 1.99M | 5.43% | 0.00% | Jun 2026 |
| Royce Micro-Cap Trust | 750K | 2.05% | +1.03% | Sep 2026 |
| First Eagle Small Cap Opportunity I | 411K | 1.12% | +1.07% | Sep 2026 |
| Royce Micro-Cap Invmt | 347K | 0.95% | +1.03% | Sep 2026 |
| Royce Capital Micro-Cap Inv | 114K | 0.31% | +1.03% | Sep 2026 |
| North Growth Canadian Equity Series F | 82.9K | 0.23% | +3.16% | Sep 2026 |
| First Eagle US Small Cap Opp I-UC | 38.0K | 0.10% | +1.40% | Sep 2026 |
| iShares S&P/TSX Small Cap ETF | 30.5K | 0.08% | -1.45% | Oct 2026 |
| NEI Growth and Income A | 30.2K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 26.7K | 0.07% | 0.00% | Aug 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 17.3K | 0.05% | +1.92% | Oct 2026 |
| Pender Alternative Special Situations A | 9.40K | 0.03% | 0.00% | Oct 2026 |
| NEI Canadian Equity A | 8.00K | 0.02% | 0.00% | Sep 2026 |
| DFA International Small Company I | 4.56K | 0.01% | 0.00% | Sep 2026 |
| North Growth Balanced Fund Series F | 4.08K | 0.01% | 0.00% | Oct 2026 |
| DFA International Core Equity 2 I | 3.81K | 0.01% | 0.00% | Sep 2026 |
| Dimensional International Core Eq 2 ETF | 1.89K | 0.01% | 0.00% | Oct 2026 |
| Dimensional International Small Cap ETF | 908.00 | 0.00% | 0.00% | Oct 2026 |
| DFA Global Small Company Institutional | 10.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding PROF.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity International Ltd | 2.37M | 6.47% | +1.28% | Jun 2026 |
| Gagnon Securities LLC | 2.05M | 5.60% | +4.62% | Sep 2026 |
| Royce & Associates, LP | 1.20M | 3.28% | +7.45% | Jun 2026 |
| Timelo Investment Management Inc. | 1.11M | 3.04% | 0.00% | Jun 2026 |
| Gagnon Advisors, LLC | 962K | 2.63% | 0.00% | Sep 2026 |
| Letko, Brosseau & Associates Inc. | 936K | 2.55% | 0.00% | Sep 2026 |
| Arnhold & S. Bleichroeder Advisers, LLC | 880K | 2.40% | +172.82% | Jun 2026 |
| Rosalind Advisors, Inc. | 828K | 2.26% | 0.00% | Jun 2026 |
| Z3 Capital Partners, LLC | 821K | 2.24% | +0.36% | Jun 2026 |
| Mmcap International Inc. Spc | 671K | 1.83% | -9.90% | Jun 2026 |
| Ardsley Advisory Partners | 575K | 1.57% | 0.00% | Jun 2026 |
| Ring Mountain Capital, LLC | 521K | 1.42% | +1.80% | Sep 2026 |
| Lagoda Investment Management LP | 501K | 1.37% | +13.68% | Jun 2026 |
| Royal Bank of Canada | 491K | 1.34% | -0.32% | Jun 2026 |
| Dafna Capital Management LLC | 260K | 0.71% | -1.01% | Jun 2026 |
| Bleichroeder LP | 255K | 0.70% | 0.00% | Jun 2026 |
| Formula Growth Ltd | 240K | 0.66% | -0.44% | Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ | 219K | 0.60% | +0.70% | Jun 2026 |
| Thompson Davis & Co Inc | 217K | 0.59% | +0.35% | Jun 2026 |
| Dauntless Investment Group, LLC | 208K | 0.57% | -13.45% | Jun 2026 |
Profound Medical Corp company profile
- Company name
- Profound Medical Corp
- Ticker
- PROF.US
- ISIN
- CA74319B5027
- Exchange
- USA Stocks
- Listed since
- Jun 9, 2016
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 162
- Fiscal year end
- December
- Address
- 2400 Skymark Avenue, Mississauga, ON, Canada, L4W 5K5
- Phone
- 647 476 1350
- Website
- profoundmedical.com
About Profound Medical Corp
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
Profound Medical Corp management
6- Dr. Arun Swarup Menawat MBA, Ph.D.Chairman of the Board & CEO · born 1955
- Dr. Mathieu Burtnyk Ph.D.Chief Technology Officer · born 1982
- Mr. Thomas Tamberrino MBAChief Commercial Officer · born 1980
- Mr. Richard R. FabianPresident · born 1967
- Mr. Stephen KilmerInvestor Relations
- Mr. Levant TinazSoftware Developer